Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Mar 15, 2025; 16(3): 99142
Published online Mar 15, 2025. doi: 10.4239/wjd.v16.i3.99142
Investigating the impact of intestinal glucagon-like peptide-1 on hypoglycemia in type 1 diabetes
Mahmoud Nassar, Angad Singh Gill, Erlin Marte
Mahmoud Nassar, Angad Singh Gill, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY 14221, United States
Mahmoud Nassar, Angad Singh Gill, Department of Research, American Society for Inclusion, Diversity, and Equity in Healthcare (ASIDE), Lewes, DE 19958, United States
Erlin Marte, Department of Endocrine, WNY VA Hospital, Buffalo, NY 14215, United States
Author contributions: Nassar M, Gill AS and Marte E contributed equally to the conceptualization, methodology, investigation, writing (original draft preparation and review & editing), and final approval of the manuscript; Each author has agreed to the published version of the manuscript.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest regarding the publication of this paper.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Mahmoud Nassar, MD, PhD, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, 705 Maple Road, Buffalo, NY 14221, United States. dr.nassar@aucegypt.edu
Received: July 14, 2024
Revised: November 30, 2024
Accepted: January 2, 2025
Published online: March 15, 2025
Processing time: 190 Days and 14.3 Hours
Core Tip

Core Tip: This study unveils a novel role of intestinal glucagon-like peptide-1 (GLP-1) in type 1 diabetes (T1D) hypoglycemia management. It reveals that increased GLP-1 and GLP-1 receptor expression in the intestine correlates with reduced adrenal and glucagon responses, which are crucial for glucose stabilization during hypoglycemic episodes. These findings suggest a significant modulation of hormonal counter-regulation pathways by intestinal GLP-1, pointing towards new therapeutic approaches that could better manage hypoglycemia in T1D without compromising natural counterregulatory mechanisms.